肝X受体——癌症治疗新靶点
| 作者: |
1刘晓旺,
1陆凯强,
1熊婷,
2周志刚,
1涂剑
1 南华大学药物药理研究所，湖南 衡阳 421001 2 南华大学第一附属医院麻醉科，湖南 衡阳 421001 |
| 通讯: |
周志刚
Email: zhouzhigang0734@sina.com 涂剑 Email: tujian0734@aliyun.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.05.030 |
| 基金: | 湖南省教育厅创新平台项目, 15K111 国家自然科学基金资助项目, 81541163 湖南省自然科学基金资助项目, 2015JJ3101 “湖南省分子靶标新药研究协同创新中心”培育项目, 2014-405 |
摘要
肝X受体(liver X receptors，LXRs)包括LXRα(NR1H3)和LXRβ(NR1H2)两种亚型，对机体的生理活动尤其代谢过程具有重要的调节作用。近年研究发现，LXRs可通过调控一系列信号转导通路抑制癌细胞增殖、侵袭、诱导凋亡等进而影响前列腺癌、乳腺癌、肝癌、黑色素瘤、白血病等多种恶性肿瘤的发生发展，成为癌症治疗新靶点。因此本文主要就LXRs在癌症网络调控的研究进展进行综述。
关键词：
肝X受体(LXRs)
癌症
治疗新靶点
Liver X receptors—a new target for cancer treatment
CorrespondingAuthor: ZHOU Zhigang Email: zhouzhigang0734@sina.com
DOI: 10.3978/j.issn.2095-6959.2016.05.030
Abstract
Liver X receptors (LXRs), including two subtypes of LXRα (NR1H3) and LXRβ (NR1H2), play an important role in regulating the physiological activities especially for metabolism of human body. Recent studies have further explored that LXRs might be one of new targets for cancer treatment because it could influence several cancer progression such as prostate cancer, breast cancer, liver cancer, melanoma, leukemia through inhibiting the proliferation and invasion and inducing the apoptosis of cancer cells. Therefore, this review will focus on the research progress of LXRs in regulatory network of cancer.